Engen Bio

Creating A Future Where Influenza Is A Thing Of The Past

Claim My Business
Security Type
Technology, Social Impact, Pets/Animals, Healthcare & Medical
Min Investment
Redwood City, CA
Offering Date
November 06, 2021
Expected Close Date
April 30, 2022
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

EnGen Bio's lead program focuses on developing an effective, easy-to-manufacture, shelf-stable vaccine and therapy to confer long-term immunity to all Type A influenza strains, including all flu pandemics, all Type A seasonal flus, and all animal flus. Our goal: with one or two shots, you could be protected from the worst seasonal influenza viruses, and all pandemic influenza strains for life. Or, if you have already been exposed or have come down with the flu, our therapy could offer you a treatment. 

Key Deal Facts

Potential for universal prevention of Type A flu and all flu pandemics in humans and animals.
Our vaccine could save 50K-250K lives a year and prevent untold suffering of millions caused by flu.
Veterinary applications to prevent all dog, horse, pig and bird flus.
Peak sales could reach 2.6B in the U.S. alone, in an $11.4B global market (not guaranteed).
8 issued flu vaccine patents in major strategic markets.
Potential for early liquidity.
Experienced team of entrepreneurs with a combined total of 6 FDA approved drugs and >50 patents.
>50% of our lead investors are biotech execs and MDs who've vetted the science & its potential.

Management Team / Advisory Board Bios

Dr. Mark Baer
Vice President of Research
20+yr R&D of therapeutic antibodies | 20+ groundbreaking academic papers | 16 issued patents | Cornell University (BA) | UNC Chapel Hill (PhD Biochemistry) | Post-doctoral fellowship (National Cancer Institute)

Dr. Geoff Yarranton
Science Advisor
35+yr biotech veteran | 20+yr C-level exec | 3 FDA-approved pharmaceuticals (Mylotarg, Bexxar, Cimzia) | 2 successful bio/pharma mergers (including IPO) | 36 US patents | University of Leicester (BSc, Hons) | NIMR (PhD) | Post-doctoral fellowship MIT
Amount Raised : $1,188,482
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

Debt is something, usually money, borrowed by one party from another. Debt is used by many corporations and individuals to make large purchases that they could not afford under normal circumstances. A debt arrangement gives the borrowing party permission to borrow money under the condition that it is to be paid back at a later date, usually with interest.

Research Reports

No reports have been submitted

Become a Reporter